Skip links

NUCLIDIUM is a 2026 Fierce 15 Honoree

NUCLIDIUM is a 2026 Fierce 15 Honoree

Being named to the #Fierce15 recognizes our work to bring the next wave of targeted radiotheranostics to more patients. This honor reflects both the scientific strength of our approach and the commitment of our team to push the boundaries of what radiotheranostics can offer to patients in areas of significant unmet need.

With our lead programs NU101 and NU201 advancing in prostate and breast cancer, 2026 is a year of steady momentum and purposeful drive.

We would like to thank the Fierce Biotech team for selecting us as one of this year’s fiercest companies and placing NUCLIDIUM among the most innovative and promising biotech companies within our industry.

The full feature is available here https://lnkd.in/d3craihN

Explore
Drag